This is a preview of subscription content, log in via an institution to check access.
References
Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society, 1996
Studd J, Arnala I, Kicovic PM, et al. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998 Oct; 92 Pt 1: 574–9
Haddad J, Delaroudis S, Avramides A, et al. The effects of tibolone on the lipid profile of postmenopausal women with osteoporosis. 66th Congress of the European Atherosclerosis Society; 1996 Jul 13–17; Florence, 55
Türkeri LN, Özyürek M, Yenice S, et al. Epithelial regression and decrease in serum PSA levels induced by short-term doxazosin treatment in benign prostatic hyperplasia. Br J Urology 1997 Sep; 80 Suppl. 2: 209
Pavlov P, Ginsburg J, Hen STA, et al. Placebo-controlled study of effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without fractures. 10th International Congress of Endocrinology I; 1996 Jun 12–15; San Francisco, 69
Patel S. Current and potential future drug treatments for osteoporosis. Ann Rheum Dis 1996 Oct; 55: 700–14
Rights and permissions
About this article
Cite this article
Tibolone. Drugs R&D 1, 225–227 (1999). https://doi.org/10.2165/00126839-199901030-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901030-00009